| Literature DB >> 31448260 |
Manuel A Rentería-Gómez1, Alejandro Islas-Jácome2, Shrikant G Pharande1, David A Vosburg1,3, Rocío Gámez-Montaño1.
Abstract
class="Chemical">6-Triazolylmethyl-pyrrolo[3,4-b]pyridin-5-one <class="Chemical">span class="Chemical">tris-heterocycles were synthesized in 43-57% overall yields. The two-stage synthesis involved a cascade process (Ugi-3CR/aza Diels-Alder/N-acylation/aromatization) followed by a copper-assisted alkyne-azide [3+2] cycloaddition (CuAAC). This efficient and convergent strategy proceeded via complex terminal alkynes functionalized with a fused bis-heterocycle at the α-position. The final products are ideal candidates for SAR studies as they possess two privileged scaffolds in medicinal chemistry: 4-substituted or 1,4-substituted 1H-1,2,3-triazoles and pyrrolo[3,4-b]pyridin-5-ones.Entities:
Keywords: CuAAC; Ugi-3CR; aza Diels-Alder; cascade IMCR process; nitrogen tris-heterocycles
Year: 2019 PMID: 31448260 PMCID: PMC6691067 DOI: 10.3389/fchem.2019.00546
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Figure 1Bioactive bis- and tris-heterocycles and our synthetic targets.
Scheme 1Previous works.
Scheme 2Cascade IMCR /[3+2] cycloaddition strategy.
Scheme 3Synthesis of 4-substituted 1H-1,2,3-triazoles 9a-l and 1,4-disubstituted 1H-1,2,3-triazoles 19a-l via an IMCR/aza Diels-Alder/N-acylation/aromatization/[3+2] cycloaddition sequence.
IMCR based cascade strategy screening conditions.
| 1 | PhMe | ——- | 65–80 | 12 | 13 |
| 2 | PhMe | NH4Cl | 65–80 | 12 | 43 |
| 3 | PhMe | NH4Cl | 65–80 | 1.5 | 57 |
| 4 | PhMe | TsOH | 65-80 | 1.5 | — |
| 5 | PhMe | Sc(OTf)3 | 65–80 | 12 | 42 |
| 7 | PhMe | Yb(OTf)3 | 65-80 | 1.5 | 62 |
1.0 equiv. .
1.0 mL solvent.
1.4 equiv.
MW (100 W).
1.5 equiv.
3.0 mol%.
isolated products.
Bold values indicate the best conditions.
Synthesis of the 6-propargyl-pyrrolo[3,4-b]pyridin-5-ones 5a-l.
| Ph | piperidine | 64 | |
| 3,4-diOMePh | piperidine | 72 | |
| 4-FPh | piperidine | 62 | |
| piperidine | 64 | ||
| Ph | morpholine | 69 | |
| 3,4-diOMePh | morpholine | 66 | |
| 4-FPh | morpholine | 66 | |
| morpholine | 67 | ||
| Ph | diethylamine | 59 | |
| 3,4-diOMePh | diethylamine | 63 | |
| 4-FPh | diethylamine | 64 | |
| diethylamine | 66 | ||
Reactions performed with 1.0 equiv. propargylamine (.
isolated products.
Scheme 4Plausible reaction mechanism.
Screening conditions for the [3+2] cycloaddition.
| 1 | 1.0 | 3 | 100 | 12 | 48 |
| 2 | 1.5 | 3 | 100 | 12 | 69 |
| 4 | 2.0 | 5 | 100 | 18 | 75 |
| 5 | 2.0 | 3 | 100 | 0.5 | 52 |
isolated products.
MW (100 W).
Bold values indicate the best conditions.
Synthesis of 4-substituted 1H-1,2,3-triazoles 9a-l.
| Ph | piperidine | 77 | |
| 3,4-diOMePh | piperidine | 75 | |
| 4-FPh | piperidine | 80 | |
| piperidine | 70 | ||
| Ph | morpholine | 63 | |
| 3,4-diOMePh | morpholine | 73 | |
| 4-FPh | morpholine | 80 | |
| morpholine | 75 | ||
| Ph | diethylamine | 73 | |
| 3,4-diOMePh | diethylamine | 70 | |
| 4-FPh | diethylamine | 78 | |
| diethylamine | 75 | ||
1.0 equiv. alkyne .
isolated products.
Scheme 5Plausible CuAAC reaction mechanism.
Synthesis of 1,4-disubstituted 1H-1,2,3-triazoles 19a-e.
| 90 | 83 | ||
| 30 | 89 | ||
| 45 | 93 | ||
| 45 | 90 | ||
1.0 equiv. azide .
isolated products.